Sorry, you need to enable JavaScript to visit this website.
Pfizer’s Worldwide Medicinal Chemistry core capabilities include small molecule design and associated functions including structural biology and computational chemistry, synthetic innovation and compound safety prediction. Our partnering strategy is designed to maintain and enhance these areas as well as generate new synergistic capabilities.

Pfizer is interested in establishing alliances to develop and access:

  • Computational methods to integrate, manage, visualize, and mine large-scale compound-centric datasets from published literature and patents
  • Technology to expand NCE target space – orally bioavailable and cell penetrable peptides, and non-Ro5 compounds
  • Natural product synthetic biology and screening technologies
  • Ion channel modulator design and screening technologies
  • Membrane protein structural biology technologies and capabilities, including ion channels, GPCRs and solute carrier proteins
  • Computational methods for quantitative affinity prediction and molecular dynamics simulation
  • New high efficiency synthetic transformations and novel flow chemistry approaches
  • Systems/chemical biology technologies enabling mechanism determination for phenotypic screening hits
  • Bioinformatic approaches to define target selectivity
  • CH activation chemistry
  • Novel synthetic methodology to access small conformationally constrained multifunctional templates
  • Novel strategies for enhancing permeability of poorly absorbed molecules
  • Novel fragment or compound collections validated for protein-protein interaction targets
  • Identification of and access to novel sub-nanomolar cytotoxic agents
  • New chemistry to develop disease imaging agents (e.g., plaques/AD, beta cells/T2D, angiogenesis/cancer
  • Novel methodology and capabilities to enable 18F chemistry
  • Biophysical techniques to enable rapid state dependent ion channel screening
  • Novel receptor mediated and transporter mediated tissue targeting strategies
  • High content and in silico approaches to predict small molecule toxicity

Not actively seeking partnering opportunities in:

  • De novo in silico approaches without wet lab experimental validation
  • Compound libraries with a limited track record of finding hits